OXFORD, England, Sept. 9, 2024 /PRNewswire/ -- U-Ploid, a
venture-backed biotechnology company, today announced the launch of
its innovative platform designed to significantly improve egg cell
quality, a critical factor in IVF success. The company's
ground-breaking technology aims to address the growing unmet need
for age-related infertility treatments.
Millions struggle with age-related female fertility decline,
placing immense emotional and financial burdens on families as they
undergo multiple failed IVF cycles. U-Ploid is dedicated to
transforming the lives of those affected, by developing an
innovative therapy that increases the likelihood for older eggs to
support viable pregnancies. The company envisions becoming a global
leader in reproductive medicine by providing effective and
accessible solutions to age-related fertility decline.
"Our team is developing technology that directly targets the
root cause of age-related female infertility," said Dr Chloe Charalambous, Co-founder & COO of
U-Ploid Biotechnologies. "By improving the health of older eggs, we
have the opportunity to help millions of people in their fertility
journey."
There is a growing need to radically improve IVF as more people
choose to start families later in life. Egg cell quality is a key
factor in fertility outcomes for would-be parents. U-Ploid's
proprietary technology repairs decades of damage accumulated by
eggs, a novel approach that aims to improve the viability of older
eggs within an IVF cycle.
"We are thrilled to introduce U-Ploid's breakthrough technology,
a significant step forward in addressing the global challenge of
age-related infertility," said Dr Jordan
Abdi, Co-founder & CEO. "By improving egg quality, we
aim to dramatically increase the propensity for successful
pregnancies through IVF."
U-Ploid is dedicated to collaborating with leading fertility
clinics to bring this transformative technology to patients. The
company is preparing clinical studies to validate the efficacy and
safety of its platform and is committed to obtaining regulatory
approvals for widespread adoption.
About U-Ploid Biotechnologies
U-Ploid is a biotechnology company developing next-generation
fertility therapeutics to address the global challenge of
age-related infertility. Co-founded by Jordan Abdi, Chloe
Charalambous, and Alexandre
Webster, U-Ploid is pioneering innovative solutions to
improve IVF outcomes and expand the window of reproductive
opportunity. The company's technology is designed to increase the
quality of older eggs, restoring their potential to support healthy
pregnancies. U-Ploid is committed to improving access to fertility
care and envisions a future where anyone who wants to start a
family, can.
Media Contact: press@u-ploid.com
View original
content:https://www.prnewswire.co.uk/news-releases/u-ploid-announces-breakthrough-technology-to-overcome-age-related-infertility-302241485.html